Session 6 – Translational research of inhibitors of cholinesterases and paraoxonases
Chair and keynote lecturer: Florian Nachon, Brétigny-sur-Orge (France)
| Time | Lecture |
|---|---|
| 08:30 | Keynote Lecture: Florian Nachon, Brétigny-sur-Orge (France) Pharmaceutical development of butyrylcholinesterase |
| 09:00 | Senior Lecture (20 min): Brian Harvey, Potchefstroom (Republic of South Africa) Selective butyrylcholinesterase inhibition induces antidepressant, pro-cognitive, and antianhedonic effects in a genetic animal model of depression: Role of acetylcholine, ghrelin, and dopamine |
| 09:20 | Senior Lecture (20 min): Diego Muñoz-Torrero, Barcelona (Spain) Leveraging templating effects of acetylcholinesterase for the development of new anti-Alzheimer drug candidates with multiple mechanisms |
| 09:40 | Senior Lecture (20 min): Yoko Suzumoto (Italy) A novel identification of anti-hypertensive drug Spironolactone as an inhibitor of Paraoxonase 2 lactonase activity |
| 10:00 | Junior Lecture (10 min flash presentation): Alice Wang (France) Development of pleiotropic prodrugs to treat Alzheimer’s disease: From conception to in vivo evaluation |
| 10:10 | Junior Lecture (10 min flash presentation): Tangui Maurice (France) The selective butyrylcholinesterase inhibitor UW-MD-95 shows symptomatic and neuroprotective effects in a pharmacological mouse model of Alzheimer’s disease |